Jaguar8
commented on
10
5
Jaguar8
commented on
$VivoPower (VVPR.US)$
VivoPower International PLC Receives Notice from Nasdaq Regarding Compliance with Form 20-F Filing Requirements
VivoPower International PLC (VVPR) has received a notice from Nasdaq regarding non-compliance with listing requirements due to delayed filing of Form 20-F for the period ending June 30, 2024. While this doesn't affect current listing status, the company has until January 20, 2025 to submit a compliance plan. The delay is attributed to significant strategic chan...
VivoPower International PLC Receives Notice from Nasdaq Regarding Compliance with Form 20-F Filing Requirements
VivoPower International PLC (VVPR) has received a notice from Nasdaq regarding non-compliance with listing requirements due to delayed filing of Form 20-F for the period ending June 30, 2024. While this doesn't affect current listing status, the company has until January 20, 2025 to submit a compliance plan. The delay is attributed to significant strategic chan...
1
7
$BridgeBio Pharma (BBIO.US)$
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
BridgeBio Pharma announced FDA approval of Attruby™ (acoramidis) for treating adults with ATTR-CM to reduce cardiovascular death and hospitalization.
The approval is based on the ATTRibute-CM Phase 3 study results, showing a 42% reduction in composite all-cause mortality and recurrent cardiovasc...
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
BridgeBio Pharma announced FDA approval of Attruby™ (acoramidis) for treating adults with ATTR-CM to reduce cardiovascular death and hospitalization.
The approval is based on the ATTRibute-CM Phase 3 study results, showing a 42% reduction in composite all-cause mortality and recurrent cardiovasc...
2
Jaguar8
reacted to
$Prime Medicine (PRME.US)$ Prime Medicine | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-ARCH Venture Fund X, L.P.(11.8%),ARCH Venture Fund X Overage, L.P.(11.8%), etc.
SEC· 17:36
SEC· 17:36
1
Jaguar8 OP MIBS : I don’t understand what you mean give me the context